keynotes, 4 plenary sessions, 2 interdisciplinary tumor boards, 5 workshops, 45 concurrent oral sessions, and 106 posters, with the 10 top scoring abstracts published with this article. For the first time ever, the SIO conference featured a clinical track designed to expose practicing clinicians to cuttingedge research about complementary therapies and provide them with practical "take home" information for integrating evidence-based complementary therapies into their clinical practice. Also notable, the conference hosted 5 patient advocate scholars and 3 research trainees from the United States, Australia, and Canada, which was made possible through an R13 grant sponsored by the National Institutes of Health's National Cancer Institute (NCI), Office of Cancer Complementary and Alternative Medicine (OCCAM). These scholars were highly engaged in the conference and contributed not only new ideas drawn from their extensive experience as patient advocates who work closely with people living with cancer, their friends, and their families, but also enthusiasm for the promise offered by integrative oncology. Conference programming was designed to bring these 2 unique and passionate groups together to encourage a growing role of patients in integrative oncology research.
Keynote addresses were presented by the pioneering oncologist in targeted therapies, John Mendelsohn, MD (University of Texas MD Anderson Cancer Center), leading stress researcher, Sonia Lupien, PhD (Fernand-Seguin Research Centre of Louis-H. Lafontaine Hospital, Department of Psychiatry, University of Montreal), and Sonia Ancoli-Israel, PhD (University of California, San Diego School of Medicine), who provided an overview of the impact of sleep and circadian rhythms in cancer patients.
In addition to Dr Mendelsohn's keynote address, the conference's theme of personalized and targeted therapy was further explored in both plenary and workshop sessions. At the first plenary session on "Personalized Integrative Oncology," Patrick Hwu, MD (The University of Texas MD Anderson Cancer Center), and Maurie Markman, MD (Cancer Treatment Centers of America), discussed how both current and future targeted cancer treatments could be individualized to help optimize cancer patients' quality of life, while at the same time minimizing treatment-related side-effects through innovative immunotherapies and clinical research. A workshop led by Elena J. Ladas, PhD, RD (Columbia University Medical Center), focused on how to develop and discuss personalized integrative treatment strategies for cancer patients, survivors, and their families. A plenary session moderated by Richard Boland, MD (Baylor University Medical Center), featured presentations by Jean-Pierre Issa, MD (Temple University), and Roderick Dashwood, PhD (Texas A&M Health Science Center), on the impact of lifestyle and natural health products on epigenetic mechanisms and the impact of these mechanisms on cancer development. These presentations emphasized how individualized lifestyle choices could have a significant impact on future cancer prevention strategies.
The Conference's clinical track focused on how to understand and use the integrative oncology evidence base to create individualized treatments for cancer patients and survivors. Richard T. Lee, MD (University of Texas MD Anderson Cancer Center), was joined by Weidong Lu, MD, PhD, MPH (Dana-Farber Cancer Institute), and Catherine Power-James, PhD (University of Texas MD Anderson Cancer Center), to review the clinical trials published in the last year in integrative oncology with a focus on how to incorporate the results into clinical practice. Two multidisciplinary integrative tumor boards focused on cancer cases that illustrated how to formulate, implement, and monitor an evidence-based and personalized integrative treatment plan.
Continuing SIO's desire to foster collaborative bridges between organizations with similar goals, a joint plenary session was presented by SIO and the American Academy of Hospice and Palliative Medicine (AAHPM; www.aahpm. org). This session featured presentations on the definition of palliative care and its role in supportive care and symptom management (Christine Ritchie, MD, MSPH, University of California San Francisco); an overview of pharmacological and nonpharmacological management of cancer symptoms (Suresh Reddy, MD, University of Texas MD Anderson Cancer Center); and a discussion of common mechanisms, phases, and assessments of cancer symptoms (Shalini Dahal, MD, University of Texas MD Anderson Cancer Center). This joint plenary session will help foster future collaborations between SIO and AAHPM that will lead to projects aimed at improving the lives of cancer patients.
A third plenary focused on highlights of articles published in a special issue of the Journal of the National Cancer Institute (JNCI) Monograph (http://jncimono.oxfordjournals. org/content/2014/50.toc), which focused on integrative oncology in cancer survivorship and included commentaries from key stakeholders, including the National Cancer Institute, NC-CAM, the American Cancer Society, SIO, the Consortium of Academic Health Centers for Integrative Medicine, and patients. In this symposium, guest editors for the monograph, . On behalf of the SIO's Clinical Guidelines Working Group, Heather Greenlee, ND, PhD (Columbia University), and Debu Tripathy, MD (University of Texas MD Anderson Cancer Center), presented the first ever published clinical practice guidelines on the use of integrative therapies for breast cancer survivors, which were developed using a systematic review process set forth by the Institutes of Medicine (Greenlee et al 4 ). These new guidelines promise to be an invaluable resource for clinicians struggling with questions from patients and families regarding the efficacy and safety of complementary therapies following a breast cancer diagnosis.
Next year, the SIO's 12th International Conference will be held in Boston, Massachusetts, from November 14 to 16, 2015. The conference theme will be "Integrated Innovation." The conference will be chaired by Patricia Arcari, PhD, RN (Dana Farber Cancer Institute), and Gary Deng, MD, PhD (Memorial Sloan Kettering Cancer Institute). For the first time, SIO will be joining the Society for Acupuncture Research (SAR; www.acupunctureresearch.org) and the Fascia Research Society (FRS; https://fasciaresearchsociety.org) to create a joint research day. This day will explore the unique intersection of oncology, Oriental medicine, and fascia research on the first day of the 12th International Conference of the SIO (November 14, 2015) at the Joseph B. Martin Conference Center at Harvard Medical School. This conference is anticipated to attract registrants from across North America, Europe, and Asia and will provide an unparalleled opportunity for collaboration and knowledge exchange in the field of integrative oncology. Background: Ancient traditional physicians from many countries used leeching to treat a wide range of diseases for thousands of years. A large number of peptides and proteins have been identified and characterized in leech saliva extract (LSE), including antithrombotic agents, cancer metastasis inhibitors, and antimicrobials. Currently, leech therapy is established as an important tool in microsurgery, and reconstructive operations having demonstrated superior clinical outcomes for the optimal salvage of grafted tissues. Methods: In the current study, we have determined the in vivo toxicity and efficacy of LSE from Hirudinaria manillensis. For the toxicity study, we used 5 groups of CD1 mice, 3 mice per group, which were subcutaneously injected with vehicle or 1, 5, 10, and 20 mg/kg of LSE twice weekly for 4 weeks. After 4 weeks, we collected blood samples for complete blood count as well as liver and kidney function tests. In addition, liver, spleen, kidney, lung, and brain tissues were collected for further toxicological analysis (ongoing).
To evaluate the in vivo efficacy of LSE in the PC3 tumor model, we used 4 groups of male nude mice, 6 mice per group, which were subcutaneously injected with 0.5 mg/kg or 1 mg/kg LSE, docetaxel (15 mg/kg) as a positive control or vehicle, respectively. Currently, we are determining the effect of LSE on the LN-CaP xenograft mouse model (ongoing study). Results: The data demonstrate that LSE is safe when administered up to 20 mg/kg with no toxicity. There is a significant decrease in the growth of PC3 xenografts with either docetaxel or LSE (1 mg/kg) treatment compared to the vehicle-treated control mice. There was no significant difference between the antitumor activity of docetaxel and LSE (1 mg/kg). There was a significant decrease in the body weight of docetaxel-treated mice while there was no change in the body weight of LSE-treated mice. Conclusions:
To our knowledge this is the first report of LSE as a safe biological agent with significant antitumor activity in the PC3 prostate cancer xenograft model with no apparent side effects.
Background: Randomized trials of acupuncture have been limited by impressive responses in the sham arm. We sought to evaluate the relationship between baseline response expectancy, a key component of the placebo effect, with pain reduction in real and sham acupuncture. Methods: We analyzed data from a randomized controlled trial using electroacupuncture (EA) and sham electro-acupuncture (SA). The trial was conducted among 67 women with stage I to III breast cancer who experienced joint pain attributable to aromatase inhibitors. Pain was measured using the Brief Pain Inventory (BPI) at baseline and Week 8 (end of intervention). The Acupuncture Expectancy Scale (AES), a validated instrument, was used to measure baseline expectancy. In this scale, a higher score indicates a greater degree of expectancy. We built a linear regression model to evaluate the association of percent BPI severity reduction with baseline AES, by treatment group. Results: In the SA group each point increase in baseline AES was associated with a greater percent BPI reduction (regression coefficient 7.9, P = .007). In the EA group, by contrast, there was no association between baseline AES and percent BPI reduction (P = .89). Regardless of AES score, the average BPI severity reduction in the EA group was always greater than 30%. Patients with a low score on the AES had better pain reduction with EA than SA. As baseline AES rose, the difference between EA and SA diminished and SA eventually surpassed EA. Conclusions: The relationship between expectancy and treatment response is distinct between real and sham acupuncture. While patients receiving EA had a clinically significant improvement in pain regardless of expectancy, patients receiving SA only gained a benefit if they expected one.
Patients with high baseline expectancy may gain equivalent benefit from a less aggressive form of acupuncture such as superficial needling with minimal manipulation.
Abstract 87
Effect Background: The use of acupuncture has been reported in a number of studies performed among children with cancer; however, demographic predictors associated with the acceptance of acupuncture are unknown. We present the results of a prospective study that evaluated predictors of use and safety of acupuncture in children and adolescents undergoing cancer treatment. Methods: Eligible participants (N = 90) were acupuncture-naïve children and adolescents with cancer who were receiving treatment for cancer at Columbia University Medical Center. After providing consent, participants completed the Memorial Symptom Assessment Scale (MSAS) every 3 weeks and were offered acupuncture. Reasons for use and acute (<24 hours) and delayed (>24 hours) side effects were collected after each acupuncture treatment. Frequencies and χ 2 analysis were performed with SAS 9.3. Results: A total of 252 sessions of acupuncture were delivered over the study period. Over half (54%) of participants requested acupuncture. Median age was 14 years (range = 1-23), with older age significantly associated with use of acupuncture use (P < .0001). Acupuncture was more often delivered to patients diagnosed with leukemia or lymphoma (P = .044). Demographic variables associated with use of acupuncture included the following: ethnicity of the patient (P = .0002), mother (P = .0003), and father (P = .00003); religion of patient's mother (P = .000001) and father (P = .00002); regular attendance of religious services (P = .0045); and household income (P = .0005). Acupuncture was requested most often for persistent symptoms and usually requested later compared to early in treatment. Most commonly, acupuncture was requested for the management of gastrointestinal-related conditions. Controlling for repeated observations, there was no increase in acute or delayed side effects related to acupuncture treatment in patients with and without thrombocytopenia (P = .189) or neutropenia (P = .497). Conclusions: Acupuncture is widely accepted and safe among children undergoing treatment for cancer. Sociodemographic variables and persistent symptom burden predict the use of acupuncture, suggesting target populations for the delivery and scientific evaluation of acupuncture in pediatric oncology.
Abstract 138

Evaluation of Active Hexose Correlated Compound (AHCC) for the Eradication of HPV Infections in Women
Background: Human papillomavirus (HPV) DNA has been detected in more than 99% of cervical cancer patients. There is currently no effective medicine or supplement for eradication of HPV infections. We previously completed preclinical in vitro and in vivo mouse data that suggested active hexose correlated compound (AHCC) will eradicate high-risk (HR) HPV infections attributed to the modulation of the expression and signaling of IFNa/b/g and may have a role in the prevention of HPV-related malignancies. The primary objective of this pilot study is to determine if AHCC is effective to eradicate cervical HR HPV infections. Methods: Women over the age of 30 that were HR HPV positive, otherwise healthy, and met the remaining eligibility criteria were enrolled in the study to evaluate the effectiveness of AHCC 3 g by mouth once daily. Once a month patients returned for a Cervista HPV HR Test (Hologic, Inc, Bedford, MA) and a 2 mL research blood sample was obtained to monitor immune markers. AHCC was continued 4 weeks beyond first negative Cervista test and then it was stopped. Patients continued in the study off treatment for another 4 weeks followed by a Cervista test to confirm eradication of HPV. Patients that had persistent HR HPV infection after 12 weeks of treatment were considered a treatment failure. Results: A total of 10 HR HPV-positive women have been enrolled on study. There has been one patient that was declared treatment failure. Three have achieved a negative HR HPV test result and the remaining 6 patients are still in the study. All patients will complete study by October 2014. Final study results will be presented at the meeting. Conclusions: Preliminary results from this pilot study are consistent with our preclinical findings that AHCC appears to be effective for eradication of HPV infections. Further investigation in a formal phase II randomized placebo-controlled study is planned.
Background: Complementary and integrative approaches to cancer treatment acknowledge the importance of treating the whole person. To establish the complete range of patient benefits from these treatment approaches, it is necessary to capture and monitor all relevant patient concerns. Until now, there has been no validated patient-reported outcome measure (PROM) specific to complementary and integrative cancer care that captures the individual patient experience. Measure Yourself Concerns and Wellbeing (MYCaW) is a patientcentered questionnaire that allows cancer patients to identify and quantify the severity of their "concerns" and well-being, as opposed to using a predetermined list. MYCaW administration is brief and aids in personalizing and prioritizing a treatment approach. Our goal was to validate the responsiveness of MYCaW scores over time and review the generalizability of the existing qualitative coding framework. Methods: Baseline and 6-week follow-up data (n = 82) from MYCaW and FACIT-SpEx questionnaires were collected for a service evaluation of the "Living Well with the Impact of Cancer" course at Penny Brohn Cancer Care. MYCaW construct validity was determined using Spearman's rank correlation; responsiveness indices were used to assess score changes over time. The existing qualitative coding framework was reviewed using a new data set (n = 158) from Ottawa Integrative Cancer Centre. Results: Good correlation between MYCaW and FACIT-SpEx scores were achieved (r = .57, P ≥ .01). MYCaW profile and concern scores were highly responsive to change: SRM = 1.02 and 1.08; effect size, 1.26 and 1.22, respectively. MYCaW scores, grouped according to clinically relevant degrees of change of FACIT-SpEx data, showed the anticipated gradient of change. Concern categories relating to spirituality and weight change were added to the coding framework to improve generalizability. Conclusions: MYCaW scores were highly responsive to change, allowing personalized patient outcomes to be collected; a modified qualitative coding framework is generalizable to a range of integrative oncology settings and patients.
Abstract 33-Oral Session: TCM and Acupuncture
Acupressure the CCOP network was a successful recruitment strategy to capture this patient population in both the community and academic settings. Final data to be presented will be updated and will include study feasibility, baseline demographics, physical activity, as well as quality of life. Background: Dietary polyunsaturated fatty acids (PU-FAs) alter the expression and secretion of a variety of adipokines in vitro and in vivo. Diets rich in omega-6 fatty acids shift the circulating leptin-adiponectin ratio in favor of leptin, whereas diets rich in omega-3 fatty acids have the opposite effect. It has been proposed that adiponectin has anticancer properties, whereas leptin and other proinflammatory adipokines may promote cancer development and growth. We tested the hypothesis that different ratios of adipose-derived factors differentially drive or inhibit normal mammary stem cell self-renewal. If the normal stem cell is the cancer cell of origin, then a larger population of these cells may be a risk factor for carcinogenesis. Methods: F344 rats were fed an obesogenic diet (high fat, high calorie) supplemented with arachidonic acid (AA) and eicosapentanoic acid (EPA) in either a 1.0 or 0.4 ratio. After 20 weeks of feeding, the animals were sacrificed and the visceral adipose explants were maintained in serum-free media (M199 supplemented with insulin and dexamethasone) for up to 10 days. Conditioned media was collected at 48 hours. Images were taken and individual adipocyte size was measured with ImageJ. Some adipose explants were fixed and stained for neutral fatty acids and actin, then visualized with confocal microscopy. Adipokine concentrations in the conditioned media were measured with the Proteome Profiler Adipokine Array (R&D Systems). Leptin was quantified by ELISA (R&D Systems) and used to normalize the relative adipokine levels measured on the array. Some of the media was size-fractionated using centrifugal filters (Amicon Ultra-15) and used to determine the fractions of conditioned media with stem cell promoting activity. Human breast tissue was collected from normal women undergoing reduction mammoplasty. Primary human mammary epithelial cells and the MCF10A and MCF-7 breast cell lines were expanded in a nonadherent sphere-forming assay as a measure of stem cell self-renewal. Cell suspensions were exposed to adipose conditioned media (1 mg/mL total protein concentration) or recombinant adipokines. After 10 days the mammospheres were collected, dissociated, and replated to form secondary spheres. MCF-10A cells were plated in nonadherent conditions and exposed to leptin or the adipose conditioned media that had been preincubated with either a leptin neutralizing antibody (R&D Systems # AF498) or a soluble chimeric leptin receptor (R&D Systems # 497-LR-100). Tumorspheres were allowed to grow for 10 days before being collected, dissociated, and replated to form secondary spheres. Results: Adipose explants were maintained in culture for up to 10 days and maintained >99% viability as assessed by trypan blue exclusion (data not shown). The secretome from the rats fed omega-6 PUFAs was enriched for leptin, resistin, and lipocalin-2. Conversely, the omega-3-rich diet led to a decrease in those pro-inflammatory adipokines and enrichment for adiponectin. Decreasing the ratio of omega-6 to omega-3 polyunsaturated fatty acids in the diet shifted the adipose-secreted adipokine ratios in favor of an anti-inflammatory and potentially anticancer axis. The adipose conditioned media from the rats fed an omega6-rich diet increased mammary stem cell selfrenewal by 75% to 115%, whereas conditioned media from the rats fed diets enriched for omega-3 PUFAs inhibited mammary stem cell self-renewal by 15% to 70% compared with baseline negative control. Selective blockade of leptin activity in the adipose conditioned media decreased stem cell self-renewal. Conclusions: The omega-6-omega-3 dietary ratio modulates the milieu of adipose-derived cytokines. The specific ratio of the adipokines influences normal and transformed mammary stem cell self-renewal. A typical Western diet enriched for omega-6 PUFAs leads to increased mammary stem cell self-renewal, whereas a diet supplemented with EPA (as found in fish oil) inhibited normal stem cell self-renewal. Since the normal mammary stem cell is likely the cell of origin in breast cancer, modulating the dietary fatty acid ratio may be a simple and effective cancer prevention strategy.
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